Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Gynecologic Cancers
•
Endometrial Cancer
•
Medical Oncology
•
Journal Club ft. NEJM publications
What are real world exclusion criteria for the use of lenvatinib + pembrolizumab for advanced endometrial cancer?
Are there specific clinical or social scenarios that would preclude the use of this treatment?
Answer from: at Community Practice
Poorly controlled Hypertension Active flare of autoimmune disease On immunosuppressant therapies
Sign in or Register to read more
Answer from: at Academic Institution
Patients with active auto-immune disease or uncontrolled hypertension should give one pause.
Sign in or Register to read more
14570
14701
Related Questions
Would you consider offering immunotherapy +/- olaparib to a patient with early-stage endometrial carcinoma for whom you are recommending adjuvant chemotherapy based on improved outcomes seen in RUBY/DUO-E/NRG-GY018?
What do you view as the future role for the combination of durvalumab + olaparib + chemotherapy in the management of patients with advanced/recurrent endometrial cancer following the DUO-E trial results?
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
When do you expect the 2023 FIGO staging for endometrial cancer to become adopted clinically in the US?
What is your preferred first line systemic treatment for recurrent, metastatic, low grade, ER/PR+ pMMR endometrioid endometrial carcinoma?
Do you screen for immune-related adrenal insufficiency for patients on immune checkpoint inhibitors?
How would you manage a POLE mutated, p53 abnormal IA myoinvasive carcinosarcoma of the endometrium with no LVSI?
What are your top takeaways in Gynecologic Cancers from ASCO 2023?
If you recommend chemotherapy for early-stage uterine serous carcinoma, do you prefer 3 or 6 cycles?
Do you recommend progesterone for endometrial protection in a young woman on estrogen replacement therapy for iatrogenic menopause after definitive radiation therapy for locally advanced cervical cancer?